Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52), Zacks reports. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%.
Lyell Immunopharma Stock Down 2.3 %
NASDAQ LYEL traded down $0.02 during trading hours on Tuesday, reaching $0.67. 482,506 shares of the company were exchanged, compared to its average volume of 1,061,552. The stock has a market capitalization of $194.49 million, a P/E ratio of -0.84 and a beta of -0.41. Lyell Immunopharma has a 1 year low of $0.51 and a 1 year high of $3.15. The business's 50 day simple moving average is $0.63 and its 200-day simple moving average is $0.94.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a report on Tuesday, November 12th.
Check Out Our Latest Stock Report on Lyell Immunopharma
Lyell Immunopharma Company Profile
(
Get Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
